Status:
COMPLETED
Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival
Lead Sponsor:
Centre Henri Becquerel
Conditions:
Lung Cancer
NSCLC
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The poor prognosis in the early-stage of lung cancer is due to potential worsening of the disease (local relapse, metastasis), to insufficient efficacy and toxicity of actual treatments. FDG-PET is a...
Eligibility Criteria
Inclusion
- Histologically confirmed non-small cell lung cancer
- Fertile patients must use effective contraception
- WHO performance status \<2
- Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (≥ 10 mm with spiral CT scan)
Exclusion
- Pregnant or lactating females
- Baseline fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scan without any target lesion
- Unable to under PET CT evaluation
- other concurrent investigational agents
- No Planning to undergo curative intent radiotherapy
- familial, social, geographic, or psychological conditions that would preclude study participation
- Prior malignancy progressive disease
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT01261598
Start Date
November 1 2007
End Date
December 1 2013
Last Update
October 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Henri Becquerel
Rouen, France, 76000